A New View of the Spectrum of HER2 Expression and Significance of HER2 Low in Breast Cancer
1:24:52
Guiding Multifactorial Clinical Decisions in HR+, HER2- Breast Cancer
3:54:38
Optogenetics: Illuminating the Path toward Causal Neuroscience
54:43
The Science of HER2-low Breast Cancer and Implications for the Pathology Team
59:34
“Hot Areas in ME/CFS Research: 2018”
1:03:59
Selecting and Sequencing of HER2-Targeting Therapies in HER2-Positive Metastatic Breast Cancer
58:05
#BREASTPATH Destiny of HER2/neu in the era of HER2-low in 2024
1:58:51
Historiker Götz Aly - Jung & Naiv: Folge 553
1:32:16